Analytical Data
-
基因名
C21orf7
- Application
-
别名
MAP3K7CL; C21orf7; TAK1LMAP3K7 C-terminal-like Protein; TAK1-like Protein
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P57077
-
表达区间
1-142aa
-
氨基酸序列
MISTARVPADKPVRIAFSLNDASDDTPPEDSIPLVFPELDQQLQPLPPCHDSEESMEVFKQHCQIAEEYHEVKKEITLLEQRKKELIAKLDQAEKEKVDAAELVREFEALTEENRTLRLAQSQCVEQLEKLRIQYQKRQGSS
-
分子量
32.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C21orf7, a gene located on chromosome 21, has garnered interest in recent years due to its potential relevance in various biological processes and diseases. This gene encodes a protein that is implicated in cellular functions such as apoptosis, cellular proliferation, and immune response, making it a candidate for studies related to cancer and autoimmune diseases. The exploration of C21orf7 as a recombinant protein has been driven by its unique structural and functional properties, which may offer insights into its role in disease mechanisms. Advances in recombinant DNA technology have enabled researchers to produce C21orf7 in sufficient quantities, allowing for detailed biochemical characterization and functional assays. This research could also help in understanding the gene's involvement in Down syndrome, given its location on chromosome 21, and its potential interactions with other genetic factors. Furthermore, studying C21orf7 may reveal new therapeutic targets or biomarkers, contributing to the development of innovative treatment strategies. Overall, the recombinant protein study of C21orf7 represents a promising frontier in biomedical research, with implications for understanding complex diseases and advancing personalized medicine.
